Cure Alzheimer's Fund is excited to share that the 21st Century Cures Act was today signed into law by President Obama. The legislation will substantially increase federal funding for medical research, and aims to improve and accelerate the approval process for new drug treatments.
The bill passed with overwhelming bipartisan support, showing widespread awareness of the need for more research funding and speedier drug development. Outside of government, the legislation was also championed by the drug industry, patient advocates, and academic institutions.
On December 5, 2016, we visited the National Institutes of Health for a conversation with Dr. Richard Hodes, director of the National Institute on Aging (NIA), about public and private efforts being made to advance Alzheimer's research.
Cure Alzheimer’s Fund is thankful to the Senate Appropriations Subcommittee for their support of increasing vital funding for Alzheimer’s disease research with the NIH. With a $400 million increase, the proposed budget for Alzheimer’s research at the NIH will reach close to $1.4 billion, nearly triple what it was three years ago, demonstrating the understanding in Congress of the need to continue to fund research to address the disease.
Cure Alzheimer's Fund is pleased to see the passage of the 21st Centuries Cures Act in the House of Representatives. The overwhelming bipartisan support for the bill shows the need for legislation to improve the process of getting to cures for life-threatening diseases like Alzheimer's.
Released today, the President's Fiscal Year 2016 Budget includes several important increases for medical research. The National Institutes of Health (NIH) will receive an additional $1 billion, incuding $68 million for the National Institute on Aging. These represent roughly a 1.1% and a 3.3% increase in NIH and NIA's respective budgets.
Senator Ed Markey (D-MA) meets with our Chairman & Co-Founder Jeff Morby. Markey and Morby discuss how Cure Alzheimer's Fund and government are working together to secure more funding for the most promising Alzheimer's research.